These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 27593891

  • 1. An innovative and highly drug-tolerant approach for detecting neutralizing antibodies directed to therapeutic antibodies.
    Sloan JH, Conway RG, Pottanat TG, Troutt JS, Higgs RE, Konrad RJ, Qian YW.
    Bioanalysis; 2016 Oct; 8(20):2157-68. PubMed ID: 27593891
    [Abstract] [Full Text] [Related]

  • 2. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
    Coddens A, Snoeck V, Bontinck L, Buyse MA, Pine SO.
    J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
    [Abstract] [Full Text] [Related]

  • 3. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
    Kavita U, Duo J, Crawford SM, Liu R, Valcin J, Gleason C, Dong H, Gadkari S, Dodge RW, Pillutla RC, DeSilva BS.
    J Immunol Methods; 2017 Sep; 448():91-104. PubMed ID: 28625864
    [Abstract] [Full Text] [Related]

  • 4. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug.
    Bourdage JS, Cook CA, Farrington DL, Chain JS, Konrad RJ.
    J Immunol Methods; 2007 Oct 31; 327(1-2):10-7. PubMed ID: 17716682
    [Abstract] [Full Text] [Related]

  • 5. Detection of antidrug antibodies against human therapeutic antibodies lacking Fc-effector functions by usage of soluble Fcγ receptor I.
    Wessels U, Poehler A, Moheysen-Zadeh M, Zadak M, Staack RF, Umana P, Heinrich J, Stubenrauch K.
    Bioanalysis; 2016 Oct 31; 8(20):2135-45. PubMed ID: 27582032
    [Abstract] [Full Text] [Related]

  • 6. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays.
    Zoghbi J, Xu Y, Grabert R, Theobald V, Richards S.
    J Immunol Methods; 2015 Nov 31; 426():62-9. PubMed ID: 26255760
    [Abstract] [Full Text] [Related]

  • 7. The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies.
    Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y.
    Front Immunol; 2020 Nov 31; 11():1951. PubMed ID: 33013848
    [Abstract] [Full Text] [Related]

  • 8. Development and validation of a cell-based SEAP reporter assay for the detection of neutralizing antibodies against an anti-IL-13 therapeutic antibody.
    Liao K, Sikkema D, Wang C, Chen K, DeWall S, Lee TN.
    J Immunol Methods; 2012 Jan 31; 375(1-2):258-63. PubMed ID: 22001556
    [Abstract] [Full Text] [Related]

  • 9. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    Mikulskis A, Yeung D, Subramanyam M, Amaravadi L.
    J Immunol Methods; 2011 Feb 28; 365(1-2):38-49. PubMed ID: 21130095
    [Abstract] [Full Text] [Related]

  • 10. Isolation of high-affinity, neutralizing anti-idiotype antibodies by phage and ribosome display for application in immunogenicity and pharmacokinetic analyses.
    Chin SE, Ferraro F, Groves M, Liang M, Vaughan TJ, Dobson CL.
    J Immunol Methods; 2015 Jan 28; 416():49-58. PubMed ID: 25449532
    [Abstract] [Full Text] [Related]

  • 11. Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody.
    Xiang Y, Parng C, Olson K, Seletskaia E, Gorovits B, Jani D, Caiazzo T, Joyce A, Donley J.
    AAPS J; 2019 Mar 29; 21(3):46. PubMed ID: 30927117
    [Abstract] [Full Text] [Related]

  • 12. Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques.
    Rosenberg YJ, Lewis GK, Montefiori DC, LaBranche CC, Lewis MG, Urban LA, Lees JP, Mao L, Jiang X.
    PLoS One; 2019 Mar 29; 14(2):e0212649. PubMed ID: 30785963
    [Abstract] [Full Text] [Related]

  • 13. A novel homogeneous Biotin-digoxigenin based assay for the detection of human anti-therapeutic antibodies in autoimmune serum.
    Qiu ZJ, Ying Y, Fox M, Peng K, Lewin-Koh SC, Coleman D, Good J, Lowe J, Rahman A, Yang J, Jiang J, Quarmby V, Song A.
    J Immunol Methods; 2010 Oct 31; 362(1-2):101-11. PubMed ID: 20868690
    [Abstract] [Full Text] [Related]

  • 14. The Immunogenicity of Biologic Therapies.
    Garcês S, Demengeot J.
    Curr Probl Dermatol; 2018 Oct 31; 53():37-48. PubMed ID: 29131036
    [Abstract] [Full Text] [Related]

  • 15. Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation.
    Wessels U, Schick E, Ritter M, Kowalewsky F, Heinrich J, Stubenrauch K.
    Bioanalysis; 2017 Jun 31; 9(11):849-859. PubMed ID: 28517957
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay.
    Hock BD, McKenzie JL, Goddard L, Smith SM, McEntyre CJ, Keating PE.
    Ther Drug Monit; 2018 Dec 31; 40(6):705-715. PubMed ID: 30439789
    [Abstract] [Full Text] [Related]

  • 18. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.
    Li J, Schantz A, Schwegler M, Shankar G.
    J Pharm Biomed Anal; 2011 Jan 25; 54(2):286-94. PubMed ID: 20869832
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.